In the ongoing battle against respiratory viruses, Professor Nathan Bartlett, a virologist at the University of Newcastle, is leading the charge with a novel nasal spray that could revolutionize our approach to preventing infections. This innovative treatment, INNA-051, is not just another vaccine; it's a game-changer in the fight against respiratory illnesses, particularly during the winter months when these viruses thrive.
A New Approach to an Old Problem
What makes INNA-051 unique is its ability to activate the body's innate immune system, the first line of defense against respiratory viruses. Unlike traditional vaccines that target specific viruses, this nasal spray enhances the body's broader antiviral response, providing protection against a range of respiratory infections, including influenza, RSV, and COVID-19. This approach is particularly intriguing because it focuses on the point of entry for these viruses - the nose.
"The idea is to boost the body's natural ability to protect itself from respiratory viruses," Professor Bartlett explains. "Most viruses, including influenza, RSV, and COVID-19, enter through the nose. If we can activate the immune system at that point of entry, we can help stop the virus before it establishes an infection."
From Discovery to Development
The journey of INNA-051 began with an unexpected discovery at Melbourne's Doherty Institute. Researchers there found that the compound behind INNA-051, originally developed to improve vaccine effectiveness, appeared to provide protection against influenza even without a vaccine. This led Professor Bartlett to take on the challenge of designing a program to prove its efficacy or lack thereof.
Over the next five years, a collaborative effort between the University of Newcastle, HMRI, and international partners in Australia and the United Kingdom tested the compound against various respiratory viruses. Professor Bartlett's role in Newcastle was pivotal, as he led the preclinical validation of the drug and its effects on viruses.
"My role in Newcastle was one of the preclinical leads working on initial validation of the drug and its effect on viruses," he recalls. "We were there at the start, getting the evidence needed to raise the money so they could go with a big clinical trial."
Clinical Trials and Real-World Impact
The early research laid the groundwork for clinical development, with Melbourne-based biotechnology company ENA Respiratory securing significant funding and a contract with the US Department of Defense. A Phase 2 clinical trial is currently underway in the United States, following a successful safety study involving 200 participants. A larger trial involving 900 people is planned for later this year, focusing on high-risk groups such as those living in university accommodation, households with young children, and childcare settings.
For Professor Bartlett, the progress is a testament to the power of scientific collaboration and the potential for real-world impact. "You hope all that work you did makes it through clinical development and eventually ends up in doctors' hands treating patients," he says. "It would protect those at high risk of nasty outcomes."
A Timely Reminder as Winter Approaches
As winter approaches, the rise in respiratory illness activity serves as a timely reminder of the ongoing challenge posed by respiratory viruses. While new treatments and preventions are crucial, Professor Bartlett emphasizes the importance of simple public health measures. "Vaccination remains one of the most effective ways to protect yourself and those around you from serious illness," he advises. "If you're unwell, stay home where possible, practise good hand hygiene, and try to avoid close contact with people who may be vulnerable."
Respiratory viruses spread easily, but small actions can make a big difference in protecting our families, workplaces, and communities. As we navigate the challenges of respiratory illnesses, Professor Bartlett's work offers a glimmer of hope, reminding us that innovation and collaboration can lead to groundbreaking solutions that improve our health and well-being.
